288 related articles for article (PubMed ID: 28709989)
1. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
[TBL] [Abstract][Full Text] [Related]
2. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
4. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
6. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
7. [Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation].
Kameda K; Miki M; Ikawa K; Morikawa N; Kobayashi M
Jpn J Antibiot; 2009 Feb; 62(1):1-8. PubMed ID: 19378765
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy.
Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T; Suyama H; Doi M; Kuwabara M
Chemotherapy; 2008; 54(5):386-94. PubMed ID: 18769027
[TBL] [Abstract][Full Text] [Related]
9. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
10. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
14. Is continuous infusion of imipenem always the best choice?
Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
17. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
Ohata Y; Tomita Y; Nakayama M; Tamura K; Tanigawara Y
J Infect Chemother; 2011 Dec; 17(6):831-41. PubMed ID: 21773752
[TBL] [Abstract][Full Text] [Related]
18. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation.
Nagasawa Z; Kusaba K; Aoki Y
J Infect Chemother; 2008 Jun; 14(3):238-43. PubMed ID: 18574662
[TBL] [Abstract][Full Text] [Related]
20. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
Santos Filho L; Eagye KJ; Kuti JL; Nicolau DP
Clin Microbiol Infect; 2007 Jun; 13(6):579-85. PubMed ID: 17331121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
